Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 7/20 | 0.50 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HPGDS | O60760 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30718022 | 0.80 | CYP11B1 (0.64) | CYP11B1CYP11B2IDO1ASIC3POLB | |
| SCHEMBL991450 | 0.77 | CYP11B1 (0.51) | CYP11B1CYP11B2IDO1ASIC3POLB | |
| SCHEMBL991449 | 0.77 | QPCT (0.58) | CYP11B1CYP11B2IDO1ASIC3POLB | |
| SCHEMBL26265591 | 0.75 | CYP11B1 (0.85) | CYP11B1CYP11B2IDO1ASIC3POLB | |
| SCHEMBL2458494 | 0.75 | DYRK1A (0.50) | CYP11B1CYP11B2IDO1ASIC3POLB | |
| SCHEMBL17800997 | 0.74 | IDO1 (0.75) | CYP11B1CYP11B2IDO1ASIC3POLB | |
| SCHEMBL2458769 | 0.73 | RIPK1 (0.50) | CYP11B1CYP11B2IDO1ASIC3POLB | |
| SCHEMBL2457010 | 0.73 | CYP11B1 (0.47) | CYP11B1CYP11B2IDO1ASIC3POLB | |
| SCHEMBL2462935 | 0.73 | DYRK1A (0.49) | CYP11B1CYP11B2IDO1ASIC3POLB | |
| SCHEMBL8337311 | 0.73 | NPC1 (0.52) | POLBTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11845745-B2 | Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment | Clavius Pharmaceuticals, LLC. (US) | 2023-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845745-B2 | Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment | TGFB1, TGFBR1, TGFB2 | CYP11B1 1086/4885CYP11B2 1006/4885IDO1 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.